PT - JOURNAL ARTICLE AU - Lally, Martin TI - The Costs and Benefits of Covid-19 Lockdowns in New Zealand AID - 10.1101/2021.07.15.21260606 DP - 2021 Jan 01 TA - medRxiv PG - 2021.07.15.21260606 4099 - http://medrxiv.org/content/early/2021/07/27/2021.07.15.21260606.short 4100 - http://medrxiv.org/content/early/2021/07/27/2021.07.15.21260606.full AB - This paper considers the costs and benefits of New Zealand’s Covid-19 nation-wide lockdown strategy relative to pursuit of a mitigation strategy in March 2020. Using data available up to 28 June 2021, the estimated additional deaths from a mitigation strategy are 1,750 to 4,600, implying a Cost per Quality Adjusted Life Year saved by locking down in March 2020 of at least 13 times the generally employed threshold figure of $62,000 for health interventions in New Zealand; the lockdowns do not then seem to have been justified by reference to the standard benchmark. Using only data available to the New Zealand government in March 2020, the ratio is similar and therefore the same conclusion holds that the nation-wide lockdown strategy was not warranted. Looking forwards from 28 June 2021, if a new outbreak occurs that cannot be suppressed without a nation-wide lockdown, the death toll from adopting a mitigation strategy at this point would be even less than had it done so in March 2020, due to the vaccination campaign and because the period over which the virus would then inflict casualties would now be much less than the period from March 2020; this would favour a mitigation policy even more strongly than in March 2020. This approach of assessing the savings in quality adjusted life years and comparing them to a standard benchmark figure ensures that all quality adjusted life years saved by various health interventions are treated equally, which accords with the ethical principle of equity across people.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNo human subjects used or referred to in the study.Funding StatementNo funding of any kind received.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Not Applicable. No human subjects used or referred in in the analysis.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data referred to in the paper is publicly available at the weblinks provided in the paper. https://www.worldometers.info/coronavirus/ https://covidtracker.bsg.ox.ac.uk/ https://www.euromomo.eu/graphs-and-maps#excess-mortality